Evidence map›Paper›PMID 38206916›Full record

ArticlePloS one2024

Nasopharyngeal carriage of Streptococcus pneumoniae among children <5 years of age in Indonesia prior to pneumococcal conjugate vaccine introduction.

Dodi Safari, Wa Ode Dwi Daningrat, Jennifer L Milucky, Miftahuddin Majid Khoeri, Wisiva Tofriska Paramaiswari, Wisnu Tafroji, Korrie Salsabila, Yayah Winarti, Amin Soebandrio, Sri Rezeki Hadinegoro and 5 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Distribution ofVaccines · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nasopharyngeal carriage and serotype distribution ofClinical and experimental vaccine research · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dodi SafariEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.ORCID 0000-0002-7639-7441
Wa Ode Dwi DaningratEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.ORCID 0000-0003-2341-5404
Jennifer L MiluckyNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.ORCID 0000-0002-1491-4669
Miftahuddin Majid KhoeriEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.
Wisiva Tofriska ParamaiswariEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.ORCID 0000-0003-2808-5248
Wisnu TafrojiEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.ORCID 0000-0003-0622-7022
Korrie SalsabilaEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.
Yayah WinartiEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.
Amin SoebandrioEijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, West Java, Indonesia.
Sri Rezeki HadinegoroFaculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Ari PrayitnoFaculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Lana ChildsCDC Foundation, Atlanta, GA, United States of America.ORCID 0000-0002-8143-2723
Fabiana C PimentaNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Maria da Gloria CarvalhoNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Tamara PilishviliNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.

Funding

Centers for Disease Control and Prevention. NU2GGH001852-03
6 · The paper itself

Abstract

Pneumococcal conjugate vaccines (PCVs) prevent nasopharyngeal colonization with vaccine serotypes of Streptococcus pneumoniae, leading to reduced transmission of pneumococci and stronger population-level impact of PCVs. In 2017 we conducted a cross-sectional pneumococcal carriage study in Indonesia among children aged <5 years before 13-valent PCV (PCV13) introduction. Nasopharyngeal swabs were collected during visits to community integrated health service posts at one peri-urban and one rural study site. Specimens were analyzed by culture, and isolates were serotyped using sequential multiplex polymerase chain and Quellung reaction. Antibiotic susceptibility was performed by broth microdilution method. We enrolled 1,007 children in Gunungkidul District, Yogyakarta (peri-urban) and 815 in Southwest Sumba, East Nusa Tenggara (rural). Pneumococcal carriage prevalence was 30.9% in Gunungkidul and 87.6% in Southwest Sumba (combined: 56.3%). PCV13 serotypes (VT) carriage was 15.0% in Gunungkidul and 52.6% in Southwest Sumba (combined: 31.8%). Among pneumococcal isolates identified, the most common VT were 6B (16.4%), 19F (15.8%), and 3 (4.6%) in Gunungkidul (N = 323) and 6B (17.6%), 19F (11.0%), and 23F (9.3%) in Southwest Sumba (N = 784). Factors associated with pneumococcal carriage were age (1-2 years adjusted odds ratio (aOR) 1.9, 95% CI 1.4-2.5; 3-4 years aOR 1.5, 95% CI 1.1-2.1; reference <1 year), other children <5 years old in the household (aOR 1.5, 95% CI 1.1-2.0), and presence of ≥1 respiratory illness symptom (aOR 1.8, 95% CI 1.4-2.2). Overall, 61.5% of the pneumococcal isolates were non-susceptible to ≥1 antibiotic class and 13.2% were multi-drug non-susceptible (MDNS) (non-susceptible to ≥3 classes of antibiotics). Among 602 VT isolates, 73.9% were non-susceptible and 19.9% were MDNS. These findings are critical to establish a pre-PCV13 carriage prevalence and demonstrate the complexity in evaluating the impact of PCV13 introduction in Indonesia given the wide variability in the carriage prevalence as shown by the two study sites.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeAnti-Bacterial AgentsCarrier StateChildChild, PreschoolCross-Sectional StudiesHumansIndonesiaInfantNasopharynxPneumococcal VaccinesSerogroupVaccines, ConjugateAnti-Bacterial AgentsPneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID38206916
PMCPMC10783721

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.